ESMO-2024: Enhertu to eclipse the standard of care in HER2+ breast cancer with brain metastases

At the European Society of Medical Oncology (ESMO) Congress 2024, recent results from the single-arm open-label DESTINYBreast-012 trial evaluating Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) in patients with metastatic BC were presented. The data demonstrated that the BCBM cohort (n=263) had a 12-month median progression-free survival (PFS) of 61.6%, with an overall response rate (ORR) of 79% for central nervous system (CNS) metastases.